Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma.

Oncotarget - 30 Jul 2015

Lu Ting-Xun, Fan Lei, Wang Li, Wu Jia-Zhu, Miao Kou-Rong, Liang Jin-Hua, Gong Qi-Xing, Wang Zhen, Young Ken H, Xu Wei, Zhang Zhi-Hong, Li Jian-Yong

Abstract excerpt

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL). Patients with DLBCL harboring MYC aberrations concurrent with BCL2 or/and BCL6 aberrations constitute a specific group with extremely poor outcome. In this study, we retrospectively investigated the incidence and prognosis of MYC, BCL2, and BCL6 aberrations with DLBCL patients in Chinese population. We applied fluorescence in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival
Share to DNA Copy Number Variations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to In Situ Hybridization, Fluorescence

Share to Incidence

Share to Lymphoma, Large B-Cell, Diffuse

Share to Multivariate Analysis

Share to Proto-Oncogene Proteins c-bcl-2

Share to Proto-Oncogene Proteins c-myc

Source

Open in PubMed Open full text

Identifiers

PMID: 26158410
DOI: 10.18632/oncotarget.4073
PMCID: PMC4621897

Genes

BCL2
MYC
BCL6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma.PMID 26158410Read ↗

MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedSemantic proximity Read ↗

Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patientsSemantic proximity Read ↗

The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

<i>MYC</i> translocation and an increased copy number predict poor prognosis in adult diffuse large B‐cell lymphoma (DLBCL), especially in germinal centre‐like B cell (GCB) typeSemantic proximity Read ↗

DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutationSemantic proximity Read ↗

Genetic heterogeneity of DLBCL, not otherwise specified.Semantic proximity Read ↗

The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP.Semantic proximity Read ↗

Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphomaSemantic proximity Read ↗

Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphomaSemantic proximity Read ↗

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapySemantic proximity Read ↗

Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B‐cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximabSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.